ArticleClinical pharmacology and therapeutics2020
Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness.
Article in Clinical pharmacology and therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04308668 (Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).Clinical drug investigation · 2020Pooled it
- Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.Annals of internal medicine · 2020Trial
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.The New England journal of medicine · 2020Trial
- Population Pharmacokinetics of Hydroxychloroquine Sulfate in Healthcare Workers, Given for Prophylaxis Against Coronavirus Disease 2019 (COVID-19) in India.Journal of clinical pharmacology · 2022Article
- A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.European journal of clinical investigation · 2022Review
- Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India.Journal of family medicine and primary care · 2022Article
- Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2.Journal of biomolecular structure & dynamics · 2021Review
- What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology.Journal of molecular cell biology · 2021Review
- Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Review
- Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.Journal of clinical pharmacy and therapeutics · 2021Review
- Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.Biochemical and biophysical research communications · 2021Review
- COVID-19: The question of genetic diversity and therapeutic intervention approaches.Genetics and molecular biology · 2021Article
- Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.Expert review of anti-infective therapy · 2021Article
- Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day.F1000Research · 2021Article
- Repurposing medications.The ocular surface · 2021Article
- Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19.Open forum infectious diseases · 2020Article
- Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19.Clinical and translational science · 2020Observational
- Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India.Journal of public health research · 2020Article
- Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.RMD open · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Hydroxychloroquine is an antimalarial drug being tested as a potential treatment for the novel coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2. Although the efficacy of hydroxychloroquine for COVID-19 remains uncertain, it may serve as a potential prophylactic agent especially in those at high risk, such as healthcare workers, household contacts of infected patients, and the immunocompromised. Our aim was to identify possible hydroxychloroquine dosing regimens through simulation in those at high risk of infections by optimizing exposures above the in vitro generated half maximal effective concentration (EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.